You are here: Industry Insights > melanoma

News List

MSD's Keytruda to treat melanoma in England on the Cancer Drugs Fund pharmafile
November 20, 2018
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) will now be made available to patients in England via the Cancer Drugs Fund, it has emerged. The new ruling covers the therapy for the treatment of melanoma following surgery in those whose cancer h
NICE rejects Opdivo for preventing melanoma recurrence pharmatimes
September 13, 2018
NHS funding for use of Bristol-Myers Squibb’s Opdivo as an adjuvant treatment for resected stage III and IV melanoma is being blocked by the National Institute for Health and Care Excellence.
BMS' Opdivo fails to win over NICE as adjuvant melanoma therapy pharmafile
September 13, 2018
Bristol-Myers Squibb has failed to convince NICE to approve the use of its PD-1 inhibitor immunotherapy Opdivo (nivolumab) as an adjuvant treatment of completely...
Researchers develop predictor for immunotherapy response in melanoma biospectrumasia
August 22, 2018
The predictor was developed by Noam Auslander, Ph.D., with other researchers in the Center for Cancer Research (CCR) at the National Cancer Institute (NCI)...
Castle study shows DecisionDx gene test predicts melanoma risks better than staging alone fiercebiotech
August 06, 2018
Castle Biosciences presented new data from a study of its DecisionDx melanoma test, showing it improved predictions of individual recurrence risk and sentinel lymph node positivity by measuring the expression of 31 genes from the primary tumor.
Incyte/MSD's immunotherapy combo fails in Phase III pharmatimes
July 17, 2018
A late stage trial testing Incyte’s epacadostat in combination with MSD’s Keytruda has failed to hit its primary targets in patients with unresectable or metastatic melanoma.
FDA approves Pierre Fabre/Array Biotech melanoma combo pharmatimes
July 05, 2018
US regulators have issued a green light for Pierre Fabre and Array Biotech’s encorafenib/binimetinib combination therapy for advanced BRAF-mutant melanoma.
Ready to challenge Novartis and Roche, Array scores FDA nod for melanoma combo fiercepharma
June 29, 2018
Twenty years after it began, Array BioPharma has its first two drug approvals, a cancer drug combo that'll transform care for certain melanoma patients, the company's CEO says. But they'll face a couple of heavyweight pharmas in the field.
Daily aspirin linked to higher risk in men worldpharmanews
May 07, 2018
Men who take once-daily aspirin have nearly double the risk of melanoma compared to men who are not exposed to daily aspirin,
FDA approves Tafinlar/Mekinist for BRAF V600-mutant melanoma europeanpharmaceuticalreview
May 03, 2018
The FDA has approved Tafinlar in combination with Mekinist for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutation…

Previous page 1 2 3 4 5 6 7 Next page